ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
Biosystems
Volume 80, Issue 1, April 2005, Pages 57-69
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (814 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.biosystems.2004.10.002    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2004 Elsevier Ireland Ltd All rights reserved.

A mathematical model of combination therapy using the EGFR signaling network

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

R.P. Araujoa, Corresponding Author Contact Information, E-mail The Corresponding Author, E.F. Petricoinb and L.A. Liottaa

aFDA-NCI Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, NCI/NIH, 8800 Rockville Pike, Building 29A, HFM 710, Bethesda, MD 20892, USA

bFDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA


Received 8 September 2004; 
revised 12 October 2004; 
accepted 13 October 2004. 
Available online 24 November 2004.

Abstract

An increasing awareness of the significance of abnormal signal transduction in tumors and the concomitant development of target-based drugs to selectively modulate aberrantly-activated signaling pathways has given rise to a variety of promising new strategies in cancer treatment. This paper uses mathematical modeling to investigate a novel type of combination therapy in which multiple nodes in a signaling cascade are targeted simultaneously with selective inhibitors, pursuing the hypothesis that such an approach may induce the desired signal attenuation with lower doses of the necessary agents than when one node is targeted in isolation. A mathematical model is presented which builds upon previous theoretical work on EGFR signaling, simulating the effect of administering multiple kinase inhibitors in various combinations. The model demonstrates that attenuation of biochemical signals is significantly enhanced when multiple upstream processes are inhibited, in comparison with the inhibition of a single upstream process. Moreover, this enhanced attenuation is most pronounced in signals downstream of serially-connected target points. In addition, the inhibition of serially-connected processes appears to have a supra-additive (synergistic) effect on the attenuation of downstream signals, owing to the highly non-linear relationships between network parameters and signals.

Keywords: Cancer treatment; Combination therapy; EGFR network; Signal transduction; Kinase inhibitors

Article Outline

1. Introduction
2. The mathematical model
3. Results
3.1. Inhibition at a single node
3.2. Inhibition at two nodes
3.2.1. Inhibition of reactions (3) and (14)
3.2.2. Inhibition of reactions (3) and (6)
3.3. Comparison of signal profiles with hypothetical ‘additive’ profiles
3.4. Feedback and cross-talk
4. Discussion and conclusions
Appendix A. Kinetic parameters
References








Corresponding Author Contact InformationCorresponding author. Tel.: +1 301 827 1740; fax: +1 301 480 3256.

Biosystems
Volume 80, Issue 1, April 2005, Pages 57-69
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.